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Abstract
Background: Two fibrosis biomarkers, galectin-3 (Gal-3) and suppression of tumorigenicity 2  
(ST2), provide prognostic value additive to natriuretic peptides and traditional risk factors in 
patients with heart failure (HF). However, it is to be investigated whether their combined meas-
urement before discharge provides incremental risk stratification for patients after acute HF.
Methods: A total of 344 patients with acute HF were analyzed with Gal-3, and ST2 meas-
ured. Patients were prospectively followed for 3.7 ± 1.3 years for deaths, and composite events 
(death/HF-related re-hospitalizations).
Results: The levels of Gal-3 and ST2 were only slightly related (r = 0.20, p < 0.001). The 
medians of Gal-3 and ST2 were 18 ng/mL and 32.4 ng/mL, respectively. These biomarkers 
compensated each other and characterized patients with different risk factors. According to the 
cutoff at median values, patients were separated into four subgroups based on high and low 
Gal-3 (HG and LG, respectively) and ST2 levels (HS and LS, respectively). Kaplan-Meier sur-
vival curves showed that HGHS powerfully identified patients at risk of mortality (Log rank = 
= 21.27, p < 0.001). In multivariable analysis, combined log(Gal-3) and log(ST2) was an in-
dependent predictor. For composite events, Kaplan-Meier survival curves showed a lower event-
-free survival rate in the HGHS subgroup compared to others (Log rank = 34.62, p < 0.001;  
HGHS vs. HGLS, Log rank = 4.00, p = 0.045). In multivariable analysis, combined 
log(Gal-3) and log(ST2) was also an independent predictor.
Conclusions: Combination of biomarkers involving heterogeneous fibrosis pathways may 
identify patients with high systemic fibrosis, providing powerful risk stratification value.  
(Cardiol J 2016; 23, 5: 563–572)
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Introduction
Heart failure (HF) is a complex clinical syn-
drome that represents the end stage of various 
cardiac diseases. In the past few decades, substan-
tial advances have been made in understanding its 
underlying pathophysiology and hemodynamics, 
and in the development of novel pharmaceuticals 
and interventional therapies. Nevertheless, short- 
and long-term HF-related re-hospitalization and 
mortality remain high, and demand substantial 
amounts of healthcare resources [1]. The limited 
effectiveness of current treatment strategies in-
dicates the need for better assessment tools for 
mechanistical phenotyping and risk stratification.
Cardiac fibrosis plays a pivotal role in the 
outcome of HF. Recently, two biomarkers indicat-
ing cardiac fibrosis, namely galectin-3 (Gal-3) and 
suppression of tumorigenicity 2 (ST2), have been 
recognized for providing risk stratification in ad-
dition to B-type natriuretic peptide (BNP) and 
N terminal-proBNP (NT-proBNP) [2]. Galectin-3, 
a b-galactoside-binding lectin, was noted to be 
higher in the serum of patients with acute decom-
pensated HF, and is independent of NT-proBNP 
in predicting short-term mortality [3–5]. ST2 
is a protein of the interleukin-1 receptor family. 
Elevated serum levels of soluble ST2 are also as-
sociated with adverse outcomes in patients with 
acute decompensated or chronic HF [6–8].
Although these two biomarkers demonstrated 
a prognostic value independent of natriuretic pep-
tides, they actually estimate global fibrosis through 
different mechanisms. Given the importance of 
assessing fibrosis in HF, combining Gal-3 and ST2 
may probably provide more information for patients 
at risk. The correlation between these two bio-
markers in acute HF is not well established. Based 
on their distinct characteristics, it is clinically 
applicable to know whether they can compensate 
each other in the scenario of estimating acute HF 
patients before discharge.
Methods
Patients and study design
The study consecutively enrolled patients 
hospitalized for acute de novo or decompensated 
chronic HF from October 15, 2008 to July 15, 2013. 
Enrollment criteria included patients (1) with 
typical signs and symptoms of HF and New York 
Heart Association (NYHA) functional classifica-
tion II to IV, who were hospitalized due to acute 
cardiogenic pulmonary congestion based on chest 
X-rays (grade ≥ I according to the classification by 
Battler et al. [9]) after non-cardiogenic causes had 
been excluded; (2) with structural abnormalities 
documented by echocardiograms; and (3) between 
20 and 85 years of age. Exclusion criteria included 
(1) having a disorder other than HF that might 
compromise survival within the next 6 months; 
(2) having been bedridden for > 3 months; 
(3) having a serum creatinine of ≥ 3 mg/dL; (4) having 
undergone dialysis within the previous 2 weeks; 
(5) having severe coronary artery disease without 
complete revascularization therapy; and (6) being 
pregnant. Informed consent was obtained from all 
the patients. The study was designed and carried 
out in accordance with the principles of the Decla-
ration of Helsinki and with approval from the Ethics 
Review Board of Chang Gung Memorial Hospital.
Blood sampling and assays
Blood samples were collected at enrollment 
during hospitalization. The measurement of BNP 
and other parameters, including estimated glo-
merular filtration rate (eGFR), hemoglobin, so-
dium, lipid profile, albumin, and C-reactive protein 
(CRP), were immediately conducted in the central 
core laboratory. The serum was stored at –80oC for 
later measurement of Gal-3 and ST2.
BNP assay
B-type natriuretic peptide was measured with 
the Triage BNP Test (Biosite, San Diego, CA), 
which was a fluorescence immunoassay for quan-
titative determination of plasma BNP. Precision, 
analytical sensitivity and stability characteristics 
of the assay were previously described [10].
Gal-3 assay
For Gal-3 measurement, an enzyme-linked 
fluorescent assay (bioMérieux ref. 411191) on 
a mini-VIDAS® analyzer (bioMérieux, France) was 
used. The total coefficient of variation for the assay 
was < 7%, the linear range was 3.3–100.0 ng/mL, 
and the limit of detection was 2.4 ng/mL.
ST2 assay
Soluble ST2 analyses were performed us-
ing the Presage ST2 assay (Critical Diagnostics, 
San Diego, CA, USA) at BG Medicine (Waltham, 
MA, USA). The average intra-assay coefficient of 
variation for sST2 was 2.7%, a total coefficient of 
variation amounted to 4.3%, and a limit of detec-
tion to 1.8 ng/mL.
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Cardiac echocardiography
Echocardiographic images were obtained with 
patients in the left lateral decubitus position at end-
expiration at 2.5 MHz (2-dimensional) (Philips iE33 
machine). The left ventricular ejection fraction was 
calculated using the Simpson method. We assessed 
the left ventricular end diastolic and end systolic di-
mensions and other associated anatomical abnormali-
ties, such as valvular lesions using criteria suggested 
by the American Society of Echocardiography.
Follow-up program
Follow-up data were prospectively obtained 
every month from hospital records, personal com-
munication with the patients’ physicians, telephone 
interviews, and patients’ regular visits to staff 
physician outpatient clinics. “Re-hospitalization” 
was defined as HF-related re-hospitalizations. 
A committee of 3 cardiologists adjudicated all hospi- 
talizations without knowledge of patients’ clinical 
variables to determine whether the events are 
related to worsening HF. “Death” was also cho-
sen as an endpoint. Deaths include sudden death 
(unexpected death, witnessed or not), worsening 
HF-related death (decompensated HF or treat-
ment-resistant HF), and of other cardiovascular 
origin (acute myocardial infarction [directly related, 
whether due to mechanic, hemodynamic, or ar-
rhythmic complications]; stroke). Because of the 
interrelationship of HF with other comorbidities, 
deaths due to comorbidities such as infection and 
multi-organ failure were also included). However, 
deaths due to cancer, surgery, suicide, or traffic ac-
cident (not related to heart) were excluded. Death 
and a composite event of HF-related re-hospital-
ization and the following death were selected as 
endpoints in this prognostic study.
Statistical analysis 
Results are expressed as mean ± standard 
deviation for continuous variables and as number 
(percentage) for categorical variables. When ap-
propriate, data were compared by 2-sample t-tests, 
c2, and one-way ANOVA (subgroup analysis was 
conducted by Tukey). Pearson’s correlation analysis 
was used to assess the correlation between Gal-3 and 
ST2. Cox proportional hazard models were used to 
determine independent predictors of the defined 
events after controlling for covariates (all param-
eters with a p value of < 0.01 in the univariate 
analysis). Hazard ratios (HRs) and 95% confidence 
intervals (CIs) were also calculated. For interpreta-
tion of these HRs, both Gal-3 and ST2 values were 
normalized by log transformation. All statistical 
analyses were 2-sided and performed using SPSS 
software (version 15.0, SPSS, Chicago, IL, USA). 
A p value of < 0.05 was considered significant.
Results
Baseline characteristics
Of 356 consecutive patients, Gal-3 and ST2 
were available for 344, who were analyzed in 
this study. The baseline characteristics of all the 
patients are shown in Table 1. Mean patient age 
was 60.6 years, 140 (40.7%) patients were equal 
to or older than 65 years old; 70.1% were men; 
and 50.3% of patients had coronary artery disease. 
Most of the patients were in NYHA functional class 
≥ III (85.5%). Regarding guideline-based medica-
tion, the use of angiotensin-converting enzyme 
inhibitors (ACEI)/angiotensin II receptor blockers 
(ARBs), and b-blockers at discharge was 85.5% and 
71.5%, respectively.
Correlations of Gal-3 ad ST2  
to demography and laboratory variables
The levels of Gal-3 were only slightly related 
to the levels of ST2 (r = 0.20, p < 0.001) (Fig. 1). 
The median of Gal-3 and ST2 were 18 ng/mL and 
32.4 ng/mL, respectively. Patients with Gal-3 above 
the median were older, had higher NYHA functional 
classes, higher incidences of diabetes mellitus 
and atrial fibrillation, were more frequently using 
diuretics, had higher levels of total bilirubin, CRP, 
BNP, and ST2, but lower high density lipoprotein 
(HDL) cholesterol levels, serum sodium, hemo-
globin, albumin, and eGFR (Table 1). Patients with 
ST2 above the median had a higher heart rate, 
higher levels of total bilirubin, BNP and Gal-3, 
were less frequently using b-blockers, and had 
lower levels of total cholesterol, HDL and low 
density lipoprotein (LDL) cholesterol, sodium, 
hemoglobin, albumin, and eGFR.
These two biomarkers of fibrosis compensated 
each other. Compared to ST2, Gal-3 was better 
associated with age, functional classes and CRP 
levels, presence of diabetes mellitus and atrial 
fibrillation, as well as using diuretics. Compared to 
Gal-3, ST2 had a better ability to identify patients 
with higher heart rate, lower total and LDL cho-
lesterol, and without using b-blockers.
Differences between subgroups  
defined by Gal-3 and ST2 levels
As a next step, based on the cutoff at the 
median values of Gal-3 and ST2, patients were 
separated into four subgroups, including high 
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Table 1. Demographic and clinical baseline characteristics by median values of galectin-3 and ST2.
All
(n = 344)
Galectin-3 ST2
≥ 18 ng/mL 
(n = 172)
< 18 ng/mL 
(n = 172)
P ≥ 32.4 ng/mL 
(n = 172)
< 32.4 ng/mL 
(n = 172)
P 
Age [years] 60.6 ± 13.4 63.1 ± 13.3 58.1 ± 12.9 0.001 60.8 ± 13.7 60.3 ± 13.1 0.760
Male 241 (70.1%) 119 (69.2%) 122 (70.9%) 0.814 123 (70.1%) 118 (68.6%) 0.638
LVEF [%] 37.0 ± 15.5 35.5 ± 15.2 38.5 ± 15.7 0.079 36.2 ± 15.4 37.9 ± 15.7 0.318
Acute 228 (66.3%) 108 (62.8%) 120 (69.8%) 0.210 109 (63.4%) 119 (69.2%) 0.305
NYHA class: < 0.001 0.092
II 50 (14.5%) 12 (7.0%) 38 (22.1%) 18 (10.5%) 32 (18.6%)
III 282 (82.0%) 152 (88.4%) 130 (75.6%) 147 (85.5%) 135 (78.5%)
IV 12 (3.5%) 8 (4.7%) 4 (2.3%) 7 (4.1%) 5 (2.9%)
BP [mm Hg]:
Systolic 123.4 ± 18.6 125.4 ± 20.1 121.5 ± 16.8 0.054 124.7 ± 19.8 122.2 ± 17.4 0.217
Diastolic 74.1 ± 12.8 74.3 ± 13.0 73.9 ± 12.7 0.791 74.3 ± 13.4 73.9 ± 12.3 0.747
Heart rate [bpm] 77.9 ± 12.3 78.9 ± 12.7 76.9 ± 11.9 0.132 79.8 ± 12.4 75.9 ± 11.9 0.003
Co-morbidity:
Diabetes mellitus 144 (41.9%) 84 (48.8%) 60 (34.9%) 0.012 79 (45.9%) 65 (37.8%) 0.155
Hypertension 231 (67.2%) 123 (71.5%) 108 (62.8%) 0.108 114 (66.3%) 117 (68.0%) 0.818
Atrial fibrillation 92 (26.7%) 55 (32.0%) 37 (21.5%) 0.038 54 (31.4%) 38 (22.1%) 0.067
COPD 37 (10.8%) 22 (12.8%) 15 (8.7%) 0.296 21 (12.2%) 16 (9.3%) 0.487
Ischemic 173 (50.3%) 86 (50.0%) 87 (50.6%) 1.0 82 (47.7%) 91 (52.9%) 0.388
BMI [kg/m2] 25.0 ± 5.7 25.0 ± 5.5 25.0 ± 5.9 0.973 24.9 ± 6.3 25.1 ± 5.1 0.815
Medication:
ACEI or ARB 294 (85.5%) 148 (86.0%) 146 (84.9%) 0.879 142 (82.6 %) 152 (88.4 %) 0.168
Beta-blocker 246 (71.5%) 119 (69.2%) 127 (73.8%) 0.403 113 (65.7%) 133 (77.3%) 0.023
Digoxin 92 (26.7%) 51 (29.7%) 41 (23.8%) 0.273 52 (30.2%) 40 (23.3%) 0.180
Diuretic 206 (59.9%) 116 (67.4%) 90 (52.3%) 0.006 110 (64.0%) 96 (55.8%) 0.153
Laboratory data:
Cholesterol [mg/dL] 176 ± 46 172.7 ± 46.7 179.7 ± 45.6 0.161 168.3 ± 45.3 184.2 ± 45.8 0.001
Triglyceride  
[mg/dL]
133 ± 110 133.4 ± 112.2 132.6 ± 108.4 0.947 122.2 ± 78.1 143.7 ± 134.1 0.070
LDL-C [mg/dL] 112 ± 40 112.5 ± 39.3 112.4 ± 41.3 0.982 107.4 ± 40.2 117.6 ± 39.7 0.019
HDL-C [mg/dL] 38 ± 16 35.4 ± 11.2 41.7 ± 20.1 < 0.001 36.4 ± 12.6 40.7 ± 19.6 0.017
Serum sodium 
[mEq/L]
138.7 ± 3.8 138.3 ± 4.4 139.1 ± 3.1 0.048 138.3 ± 4.1 139.2 ± 3.5 0.041
Hemoglobin  
[g/dL]
13.4 ± 1.9 13.2 ± 2.1 13.7 ± 1.8 0.006 13.2 ± 2.0 13.7 ± 1.9 0.035
Total bilirubin  
[mg/dL] 
1.1 ± 0.6 1.2 ± 0.8 0.9 ± 0.5 0.001 1.2 ± 0.8 0.9 ± 04 < 0.001
Albumin [g/dL] 3.6 ± 0.5 3.4 ± 0.5 3.7 ± 0.5 < 0.001 3.5 ± 0.5 3.6 ± 0.5 0.002
eGFR [mL/min/ 
/1.73 m2]
69.3 ± 26.8 56.7 ± 25.2 81.0 ± 23.2 < 0.001 65.8 ± 27.6 72.8 ± 25.7 0.015
C-reactive protein 
[mg/L]
21.9 ± 37.4 27.0 ± 44.4 16.7 ± 27.9 0.011 23.2 ± 38.5 20.6 ± 36.3 0.515
B-type natriuretic 
peptide [pg/mL]
635 ± 749 843.3 ± 901.0 427.0 ± 478.8 < 0.001 772.4 ± 848.8 497.9 ± 608.2 0.001
Galectin 3 [ng/mL] 22.8 ± 16.9 32.5 ± 19.6 13.2 ± 3.0 < 0.001 24.9 ± 18.0 20.8 ± 15.6 0.022
ST2 [ng/mL] 48.3 ± 46.1 57.6 ± 52.5 39.0 ± 36.7 < 0.001 76.9 ± 50.7 19.7 ± 7.3 < 0.001
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; BMI — body mass index; BP — blood pressure;  
COPD — chronic obstructive pulmonary disease; chronic kidney disease, estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2; 
HDL-C — high density lipoprotein-cholesterol; LDL-C — low density lipoprotein-cholesterol; LVEF — left ventricular ejection fraction;  
NYHA — New York Heart Association
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Gal-3 and high ST2 (HGHS), high Gal-3 and low 
ST2 (HGLS), low Gal-3 and high ST2 (LGHS), and 
low Gal-3 and low ST2 (LGLS). Table 2 shows the 
differences in demography and laboratory data be-
tween the four subgroups. Compared to patients in 
the LGLS subgroup, those in the HGHS subgroup 
were older, had higher NYHA functional classes and 
heart rate, higher incidences of diabetes mellitus 
and atrial fibrillation, were more frequently using 
diuretics, had higher levels of total bilirubin, and 
BNP, but lower total and HDL cholesterol levels, 
hemoglobin, albumin, and eGFR.
Death
During a mean follow-up period of 3.7 ± 1.3 
years, there were 90 (26.2%) deaths, including 
50 (55.6%) sudden deaths and 40 deaths due to 
other reasons. In a univariate analysis, associates of 
death included age, a history of previous HF, func-
tional class, hemoglobin, albumin, eGFR, log(BNP), 
log(Gal-3), log(ST2), and combined log(Gal-3) and 
log(ST2) (Table 3). Patients with decompensated 
HF (with previous HF history) might have had re-
nal fibrosis resulting in worse outcomes compared 
to those with acute HF (de novo). Gal-3 is closely 
related to renal fibrosis. Kaplan-Meier curves show 
that patients with decompensated HF and elevated 
Gal-3 had worse outcomes than others (Log rank 
= 16.72, p = 0.001) (Fig. 2A). Survival was further 
analyzed according to the four subgroups based 
on Gal-3 and ST2 levels (Kaplan-Meier survival 
curves in Figure 3A). Patients in the HGHS sub-
group had significantly higher accumulated mortal-
ity rate than other subgroups (Log rank = 21.27, 
p < 0.001). In a multivariable analysis, combined 
log(Gal-3) and log(ST2) was an independent pre-
dictor (Table 3).
Death or HF-related re-hospitalization
During follow-up there were 64 (18.6%) HF-
-related re-hospitalizations, and 122 (35.5%) com-
posite events of death/HF-related re-hospitaliza-
tions. In a univariate analysis, associates of com-
posite events included age, sex, history of previous 
HF, functional class, hemoglobin, albumin, eGFR, 
log(BNP), log(Gal-3), log(ST2), and combined 
log(Gal-3) and log(ST2) (Table 4). Patients with 
decompensated HF also had worse outcomes com-
pared to those with acute HF. Kaplan-Meier curves 
show again that patients with decompensated HF 
and elevated Gal-3 had the worst outcomes (Log 
rank = 42.05, p < 0.001) (Fig. 2B). Survival was 
further analyzed according to the four subgroups 
(Kaplan-Meier survival curves in Figure 3B). 
Patients in the HGHS subgroup has significantly 
higher accumulated mortality rate than all other 
subgroups (Log rank = 34.62, p < 0.001; HGHS vs. 
HGLS, Log rank = 4.00, p = 0.045). In multivari-
able analysis, combined log(Gal-3) and log(ST2) 
remained an independent predictor (Table 4).
Discussion
In the population of patients with acute HF, 
combined measurement of Gal-3 and ST2 during 
the acute stage in the hospital significantly and 
independently predicted long-term outcomes in 
terms of death and the composite event of death, 
as well as HF-related re-hospitalization. Combined 
measurement provided advanced risk stratification 
value compared to Gal-3 or ST2 measured alone in 
both study endpoints.
In patients with chronic HF, Gal-3 has been 
shown to provide incremental prognostic value 
over BNP [11–13]. In patients with acute HF, its 
prognostic value was demonstrated as well in 
a few studies, most of which, however, had a rela-
tively small sample size or short follow-up period. 
A few studies in acute HF patients reported that 
ST2 provided good prognostic values. In a brief 
communication, Mueller et al. [6] reported that 
increased ST2 concentrations predicted 1-year 
mortality in 137 patients with acute destabilized 
HF. Later on, Pascual-Figal et al. [7] demonstrated 
that ST2 provided prognostic value in addition to 
NT-proBNP and high-sensitivity troponin T in 107 
patients with acutely decompensated HF. Recently, 
Figure 1. Correlations between galectin-3 (Gal-3) and 
suppression of tumorigenicity 2 (ST2). Log transforma-
tion is performed for Gal-3 and ST2 [log(Gal-3) and 
log(ST2), respectively].
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Lassus et al. [8] conducted an international collabo-
rative study on patients hospitalized for acute HF, 
and showed that ST2 predicted 30-day and 1-year 
mortality. However, these data were analyzed from 
Table 2. Demographic and clinical baseline characteristics in different populations defined by the  
levels of galectin-3 and ST2.
HGHS 
(n = 100)
HGLS 
(n = 72)
LGHS 
(n = 72)
LGLS 
(n = 100)
P
Age [years] 64.61 ± 13.26* 60.89 ± 13.17 55.47 ± 12.56* 59.95 ± 13.03 < 0.001
Male 66 (60.0%) 53 (73.6%) 57 (79.2%) 65 (65.0%) 0.152
Left ventricular ejection fraction [%] 36.34 ± 15.31 34.42 ± 15.18 35.93 ± 15.53 40.31 ± 15.62 0.070
Acute 59 (59%) 49 (68.1%) 50 (69.4%) 70 (70%) 0.332
NYHA functional class: 0.004
II 5 (5.0%)** 7 (9.7%)* 13 (18.1%) 25 (25.0%)
III 90 (90.0%)** 62 (86.7%)* 57 (79.2%) 73 (73.0%)
IV 5 (5.0%) 3 (4.2%) 2 (2.8%) 2 (2.0%)
Blood pressure [mm Hg]:
Systolic 126.76 ± 21.14 123.4 ± 18.68 121.8 ± 17.43 121.3 ± 16.42 0.165
Diastolic 73.24 ± 13.39 75.75 ± 21.14 75.85 ± 13.25 72.54 ± 12.17 0.216
Heart rate [bpm] 80.12 ± 12.08** 77.15 ± 13.38 79.47 ± 12.89* 75.01 ± 10.74 0.016
Co-morbidity:
Diabetes mellitus 52 (52.0%)* 32 (44.0%) 27 (37.5%) 33 (33.0%) 0.042
Hypertension 70 (70.0%) 53 (73.6%) 44 (61.1%) 64 (64.0%) 0.338
Atrial fibrillation 39 (39.0%)* 16 (22.2%) 15 (20.8%) 22 (22.0%) 0.013
COPD 15 (15.0%) 7 (9.7%) 6 (8.3%) 9 (9.0%) 0.437
Ischemic 48 (48.0%) 38 (52.8%) 34 (47.2%) 53 (53.0%) 0.813
Body mass index [kg/m2] 24.58 ± 6.1 25.56 ± 4.57 25.41 ± 6.51 24.73 ± 5.47 0.614
Medication
ACEI or ARB 82 (82.0%) 66 (91.7%) 60 (83.3%) 86 (86.0%) 0.323
Beta-blocker 62 (62.0%) 57 (79.2%) 51 (70.8%) 76 (76.0%) 0.057
Digoxin 36 (36.0%) 15 (20.8%) 16 (22.2%) 25 (25.0%) 0.087
Diuretic 66 (66.0%)** 50 (69.4%)** 44 (61.1%) 46 (46.0%) 0.006
Laboratory data:
Cholesterol [mg/dL] 164.5 ± 44.0** 184.0 ± 48.2 173.4 ± 46.9 184.2 ± 44.23 0.008
Triglyceride [mg/dL] 126.0 ± 68.2 143.6 ± 153.3 116.9 ± 89.8 143.9 ± 119.1 0.311
LDL-C [mg/dL] 105.3 ± 38.1 122.5 ± 38.9 110.3 ± 42.9 114.0 ± 40.1 0.051
HDL-C [mg/dL] 34.33 ± 10.9** 36.8 ± 11.3** 39.3 ± 14.0 43.45 ± 23.4 0.006
Serum sodium [mEq/L] 137.8 ± 4.3 138.9 ± 4.4 138.8 ± 3.5 139.3 ± 2.6 0.056
Hemoglobin [g/dL] 12.7 ± 2.0** 13.7 ± 2.0 13.9 ± 1.7 13.6 ± 1.8 < 0.001
Total bilirubin [mg/dL] 1.2 ± 0.8** 1.0 ± 0.5 1.0 ± 0.5* 0.8 ± 0.3 < 0.001
Albumin [g/dL] 3.3 ± 0.5** 3.5 ± 0.4** 3.6 ± 0.4 3.7 ± 0.4 < 0.001
eGFR [mL/min/1.73 m2] 54.6 ± 24.1** 61.8 ± 26.23** 81.3 ± 24.5 80.7 ± 22.3 < 0.001
C-reactive protein [mg/L] 28.7 ± 45.0 24.8 ± 43.9 15.8 ± 25.4 17.6 ± 29.7 0.074
B-type natriuretic peptide [pg/mL] 984.3 ± 957.4** 739.9 ± 750.1** 540.3 ± 522.1 338.8 ± 407.1 < 0.001
*p < 0.05,**p < 0.01 compare to LGLS; HG and LG indicate galectin-3 ≥ 18 ng/mL and < 18 ng/mL, respectively. HS and LS indicate  
ST2 ≥ 32.4 ng/mL and < 32.4 ng/mL, respectively; ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; 
COPD — chronic obstructive pulmonary disease; chronic kidney disease, estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2; 
HDL-C — high density lipoprotein-cholesterol; LDL-C — low density lipoprotein-cholesterol; NYHA — New York Heart Association
cohorts with relatively short periods of follow-up. 
Our study, enrolling more patients with a longer 
period of follow-up, supported the prognostic value 
of Gal-3 and ST2 in hospitalized HF patients.
568 www.cardiologyjournal.org
Cardiology Journal 2016, Vol. 23, No. 5
As shown in our data, although both Gal-3 
and ST2 are supposed to estimate the severity 
of global fibrosis, their correlation is weak. They 
assess fibrosis by different mechanisms. Gal-3 is 
expressed by activated macrophages and stimu-
lates cardiac fibroblasts to proliferate and modulate 
Table 3. Cox univariable and multivariable analysis for death.
Item Univariable Multivariable
Hazard ratio (95% CI) P Hazard ratio (95% CI) P 
Age [years] 1.058 (1.039~1.078) < 0.001 1.050 (1.032~1.069) < 0.001
Sex 0.730 (0.477~1.117) 0.147
LVEF [%] 0.991 (0.977~1.005) 0.209
Acute (de novo) 0.523 (0.349~0.785) 0.002 0.590 (0.388~0.896) 0.013
NYHA class 4.744 (2.693~8.357) < 0.001 3.482 (1.881~6.445) < 0.001
Diabetes mellitus 1.302 (0.862~1.967) 0.210
Hypertension 1.161 (0.741~1.821) 0.515
Atrial fibrillation 1.395 (0.897~2.168) 0.140
Cholesterol [mg/dL] 0.996 (0.991~1.001) 0.096
Serum sodium [mEq/L] 0.977 (0.930~1.026) 0.344
Hemoglobin [g/dL] 0.840 (0.758~0.930) 0.001 1.003 (0.899~1.119) 0.956
Serum albumin [g/dL] 0.383 (0.261~0.564) < 0.001 0.573 (0.378~0.870) 0.009
eGFR [mL/min/1.73 m2] 0.984 (0.975~0.992) < 0.001 1.000 (0.991~1.008) 0.933
C-reactive protein [mg/L] 1.004 (0.999~1.009) 0.100
BNP (log) 2.880 (1.884~4.401) < 0.001 2.090 (1.345~3.246) 0.001
Galectin-3 (log) 5.792 (2.232~12.280) < 0.001
ST2 (log) 2.652 (1.473~4.773) 0.001
Galectin-3 (log)+ST2 (log) 3.057 (2.008~4.654) < 0.001 2.088 (1.264~3.448) 0.004
BNP — B-type natriuretic peptide; CI — confidence interval; eGFR — estimated glomerular filtration rate; LVEF — left ventricular ejection  
fraction; NYHA — New York Heart Association; ST2 — suppression of tumorigenicity 2
Figure 2. Kaplan-Meier estimates of event risk according to acute/decompensated heart failure (HF) and biomarkers; 
A. Kaplan-Meier curves for 5-year mortality stratified by acute (de novo)/decompensated HF, and galectin-3 levels; 
B. Kaplan-Meier curves for 5-year composite events of mortality or HF-related re-hospitalization stratified by acute/ 
/decompensated HF, and galectin-3 levels; A and D — acute (de novo) and decompensated HF, respectively; HG and 
LG — galectin-3 ≥ 18 ng/mL and < 18 ng/mL, respectively.
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Table 4. Cox univariable and multivariable analysis for heart failure-related re-hospitalization and death.
Item Univariable Multivariable
Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Age [years] 1.044 (1.029~1.060) < 0.001 1.036 (1.021~1.051) < 0.001
Sex 0.627 (0.434~0.908) 0.013
LVEF [%] 0.991 (0.979~1.004) 0.169
Acute (de novo) 0.456 (0.320~0.651) < 0.001 0.548 (0.379~0.790) 0.001
NYHA class 3.722 (2.218~6.245) < 0.001 2.615(1.576~3.352) < 0.001
Diabetes mellitus 1.416 (0.988~2.031) 0.058
Hypertension 1.418 (0.946~2.127) 0.091
Atrial fibrillation 1.351 (0.916~1.992) 0.129
Cholesterol [mg/dL] 0.997 (0.992~1.001) 0.096
Serum sodium [mEq/L] 0.972 (0.932~1.014) 0.189
Hemoglobin [g/dL] 0.791 (0.720~0.870) < 0.001 0.907 (0.819~1.005) 0.061
Albumin [g/dL] 0.467 (0.339~0.665) < 0.001 0.801 (0.556~1.153) 0.233
eGFR [mL/min/1.73 m2] 0.983 (0.976~0.991) < 0.001 1.000 (0.992~1.008) 0.999
C-reactive protein [mg/L] 1.003 (0.999~1.007) 0.160
BNP (log) 2.963 (2.035~4.315) < 0.001 2.299 (1.576~3.352) 0.001
Galectin-3 (log) 5.413 (2.844~10.30) < 0.001
ST2 (log) 2.516 (1.489~4.249) 0.001
Galectin-3 (log)+ST2 (log) 2.875 (1.840~3.795) < 0.001 2.072 (1.373~3.128) 0.001
BNP — B-type natriuretic peptide; CI — confidence interval; eGFR — estimated glomerular filtration rate; LVEF — left ventricular ejection  
fraction; NYHA —New York Heart Association; ST2 — suppression of tumorigenicity 2
Figure 3. Kaplan-Meier estimates of event risk according to biomarkers; A. Kaplan-Meier curves for 5-year mortality strati-
fied by high galectin-3 and high ST2 (HGHS), low galectin-3 and low ST2 (LGLS), HGLS, and LGHS; B. Kaplan-Meier curves 
for 5-year composite events of mortality or heart failure-related re-hospitalization stratified by the same four subgroups; 
HG and LG — galectin-3 ≥ 18 ng/mL and < 18 ng/mL, respectively; HS and LS — ST2 ≥ 32.4 ng/mL and < 32.4 ng/mL, 
respectively.
extracellular matrix formation, followed by adverse 
cardiac remodeling [14, 15]. Based on these mo-
lecular mechanisms, Gal-3 appears to be a direct 
mediator of fibrosis. Decompensated chronic HF is 
associated with systemic involvement of fibrosis, 
especially in renal pathology. Our data showed 
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a close relationship between Gal-3 levels and 
eGFR. Moreover, decompensated chronic HF along 
with elevated Gal-3 levels appear to be at the high-
est risk of events. Interleukin (IL)-33, a functional 
ligand of ST2, intensifies antihypertrophic and an-
tifibrotic effects on myocardium. Soluble ST2 acts 
as a decoy receptor of IL-33 and attenuates its car-
dioprotective properties [14, 15]. Our clinical data 
suggest that different biomarkers identify different 
populations with increased fibrosis activity. Except 
for a few common prognosis-relevant factors, each 
marker has its role in discovering other risk fac-
tors related to fibrosis and may provide further 
compensatory information when used together.
Previous studies in ambulatory HF patients 
revealed that Gal-3 level remained relatively 
steady and only changed over periods of months 
[16]. However, some studies have shown rapid 
dynamic changes of ST2, comparable to BNP 
[8, 17, 18]. Measuring both biomarkers in the 
meanwhile before hospital discharge may integrate 
information by combining the basal fibrosis activity 
provided by Gal-3 and the acutely increased fibrotic 
stress provided by ST2. Based on our study, we 
found that broader coverage of fibrosis defined by 
either an elevated Gal-3 or ST2 did not give rise 
to better prognostic evaluation. An increase in one 
biomarker together with a decrease in the other 
actually explored the weak prognostic value pro-
vided by a single marker alone. This phenomenon 
was noted especially when estimating the risk of 
mortality, which could be predicted only in those 
with an increase in both biomarkers. To predict 
composite events, there was a gradient trend with 
the highest risk seen in patients with high Gal-3 
and high ST2 levels, followed by those with high 
Gal-3 but low ST2 levels. Activation of two differ-
ent pathways associated with fibrosis, as suggested 
by an elevation in both Gal-3 and ST2, indicates 
a stronger systemic fibrotic activity.
Limitations of the study
Some limitations should be acknowledged. 
The present study has a relatively small sample 
size with various etiologies of HF. To better predict 
an HF-related event, a recent study performed by 
Boisot et al. [18] demonstrated that serial measure-
ments of ST2 might be needed. Acute HF patient 
with ≥ 15.5% decline in ST2 levels during the 
hospital stay had a lower short-term (90-day) mor-
tality than those with < 15.5% decrease (7% vs. 
33%) [18]. Our study cannot answer whether serial 
measurements of ST2 changes during hospitaliza-
tion may provide better evaluation than measuring 
both Gal-3 and ST2 simultaneously, in terms of 
cost or efficiency. However, serial measurements 
of both biomarkers in patients while in stable sta-
tus are believed to better clarify the relationship 
between these two markers.
On the other hand, kidney dysfunction is 
a poor prognostic parameter, and may interfere 
with Gal-3 and ST2 levels. Kidney dysfunction also 
influences the concentrations of blood albumin and 
erythropoietin, which is related to hemoglobin. In 
order to represent the information encountered in 
the real world and also to diminish the influence of 
kidney dysfunction on the data analysis, this study 
excluded patients with a serum creatinine level 
of ≥ 3 mg/dL, and included eGFR in the panel of 
multivariable analysis models.
Conclusions
Combination of biomarkers involving hetero-
geneous fibrosis pathways may identify patients 
with high systemic fibrosis activity and provide 
powerful risk stratification value.
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